Your Translational Partner in CNS Drug Discovery
We #ThinkRare.
Advancing Neuroscience. Delivering Results.
”We founded Ulysses with a singular purpose: to bridge the gap between laboratory discovery and patient benefit. Today, we're proud to be the translational partner that pharmaceutical innovators and rare disease foundations trust to accelerate treatments for the most challenging neurological conditions.
Dr. Massimiliano Bianchi, PhDFounder / President & CEO at Ulysses Neuroscience Ltd
Who We Are
Ulysses Neuroscience is an Irish Contract Research Organization (CRO) delivering integrated preclinical and clinical research services in neuroscience. We specialize in accelerating drug discovery for neuropsychiatric, neurodegenerative, and rare neurological disorders.
What sets us apart is our deep commitment to the rare disease community. We partner with patient foundations and advocacy groups to advance biomarker discovery, patient-focused clinical trials, and biocollection programs for conditions including CDKL5 Deficiency Disorder, Fragile X Syndrome, and Rett Syndrome.
Founded in 2019 by Dr. Massimiliano Bianchi—an internationally recognized expert in neuropharmacology, synaptic plasticity, and microtubule dynamics—our team brings together leading neuroscientists, clinicians, and drug development specialists. We translate scientific discovery into treatments that matter.
Our Mission
We exist to accelerate the journey from scientific discovery to patient benefit.
Through integrated preclinical and clinical research, we help pharmaceutical companies, biotech innovators, and rare disease foundations develop transformative treatments for complex brain conditions. Our approach combines rigorous science with translational expertise—from biomarker validation to patient-centric trial design—ensuring that every project moves closer to real-world impact.
Our Vision
A future where every neurological condition has a pathway to effective treatment.
We are building the world’s leading translational neuroscience CRO—one that transforms high-quality research into personalized, biomarker-driven therapies. Through scientific excellence and strategic partnerships, we aim to set new standards for how neuroscience discoveries reach the patients who need them most.
Our Values
We are guided by an unwavering commitment to scientific excellence and patient-centered purpose. Every study we conduct is designed for rigor, reproducibility, and real-world relevance—because the patients waiting for treatments deserve nothing less.
We believe in the power of partnership. By collaborating closely with pharmaceutical companies, biotech innovators, and rare disease foundations, we create flexible, tailored solutions that adapt to each project’s unique scientific and regulatory demands.
